COVID-19 vaccine reaches phase-2 trials in China
Share - WeChat

BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- China enhances coastal ecosystem protection and restoration
- Jiangsu presents innovation-driven growth and economic leadership
- China Prospectors Conference calls for AI in mineral exploration
- Tsinghua, PKU condemn sale of campus lake water
- Journalists explore Jiangsu's innovation and development achievements
- 13 new China-Uzbek vocational education tie-ups signed